Volume 32 1973

Psycho—pharmacologia

Managing Editors

J. O. Cole M. Hamilton E. Jacobsen C. Kornetsky R. W. Russell

Editorial Board

D. Bovet, Sassari J. O. Cole, Boston J. Delay, Paris J. Elkes, Baltimore
M. Hamilton, Leeds H. Isbell, Lexington E. Jacobsen, København
M. E. Jarvik, Los Angeles S. S. Kety, Boston C. Kornetsky, Boston
R. W. Russell, Bedford Park M. Shepherd, London Hannah Steinberg, London
E. Strömgren, Risskov A. Wikler, Lexington

Advisory Board

M. Adler, Philadelphia N.-E. Anden, Göteborg J. Angst, Zürich J. B. Appel, Columbia, SC
S. Barondes, La Jolla A. M. Barrett, Leeds H. Barry III, Pittsburgh H. Blaschko, Oxford
D. Booth, Birmingham H. Brill, New York
P. Carlton, New Brunswick C. K. Connors, Boston P. B. Dews, Boston
A. DiMascio, Boston E. Domino, Ann Arbor J. C. Eccles, Buffalo
U. S. von Euler, Stockholm A. Fessard, Paris M. Fink, New York
S. Fisher, Boston R. Fog, Roskilde S. Garattini, Milano S. Gershon, New York
S. C. Goldberg, Chevy Chase S. Grossman, Chicago L.-M. Gunne, Uppsala
H. Hanson, West Point J. Harvey, Iowa City H. E. Hill, Lexington
R. Hinde, Cambridge H. Hippius, München L. E. Hollister, Palo Alto
O. Hornykiewicz, Toronto E. Hosoya, Tokyo R. P. Hullin, Leeds S. Irwin, Portland
J. Jaffe, Washington W. Janke, Düsseldorf R. Jewett, Atlanta
R. T. Jones, San Francisco M. Jouvet, Lyon C. R. B. Joyce, Basel D. Joyce, London
M. Katz, Chevy Chase R. Kelleher, Boston K. F. Killam, Davis
G. Klerman, Boston N. S. Kline, Orangeburg M. H. Lader, London I. P. Lapin, Leningrad
L. Lasagna, Rochester V. Laties, Rochester A. Latz, Tel-Aviv
O. Lingjærde, Tromsø R. Lipman, Rockville A. Lubin, San Diego E. Marley, London
W. R. Martin, Lexington J. L. McGaugh, Irvine D. E. McMillan, Chapel Hill
N. Mello, Washington A. Mirsky, Boston C. Niemegeers, Beerse
S. Norton, Kansas City D. Overton, Philadelphia G. Pampiglione, London P. Pichot, Paris
R. W. Pickens, Minneapolis A. Randrup, Roskilde D. Richter, Epsom K. Rickels, Philadelphia
R. Rodnight, London J. M. Rose, Leeds R. T. Rubin, Los Angeles J. Scheel-Krüger, Roskilde
J. Schildkraut, Boston C. Schuster, Chicago C. Shagass, Philadelphia
P. Silverman, Macclesfield, Ches. F. Sjöqvist, Stockholm J. R. Smythies, Edinburgh
F. Sulser, Nashville R. Taber, Bloomfield T. Thompson, Minneapolis S. Udenfriend, Bethesda
H. Weil-Malherbe, Washington A. Weissman, Groton, CT T. Yanagita, Kawasaki
E. Zaimis, London O. Zangwill, Cambridge

Springer-Verlag
Berlin Heidelberg New York

The exclusive copyright for all languages and countries, including the right for photomechanical and any other reproductions, also in microform, is transferred to the publishers.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Springer-Verlag Berlin Heidelberg New York

Printed in Germany by Wiesbadener Graphische Betriebe GmbH, Wiesbaden

© by Springer-Verlag Berlin Heidelberg 1973

Contents

Subject Index VII

Allen, S. R., Oswald, I.: The Effects of Perlapine on Sleep 1
Altier, H., see Monti, J. M. 343

Baugh, E. L., see Drew, W. G., *et al.* 171
Bech, P., Rafaelsen, L., Rafaelsen, O. J.: Cannabis and Alcohol: Effects on Estimation of Time and Distance 373
Bond, A. J., Lader, M. H.: The Residual Effects of Flurazepam 223
Borgesová, M., see Kršiak, M. 201
Branchey, L., Friedhoff, A. J.: The Influence of Ethanol Administered to Pregnant Rats on Tyrosine Hydroxylase Activity of Their Offspring. . . 151

Candy, J., see Tyrer, P., *et al.* 237
Carvalho, F. V., see Palermo Neto, J. 383
Chan, T. L., see Sakalis, G., *et al.* 279
Chapouthier, G., see Milhaud, C., *et al.* 293
Charap, A. D., see Glick, S. D., *et al.* 365
Costall, B., Naylor, R. J.: Is There a Relationship between the Involvement of Extrapyramidal and Mesolimbic Brain Areas with the Cataleptic Action of Neuroleptic Agents and Their Clinical Antipsychotic Effect? 161
Coyle, I. R., see Singer, G. 337
Croucher, T., Hindmarch, I.: The Spiral After Effect (SAE) as a Measure of Motion Sickness Susceptibility and the Effect on the SAE of an Antimotion Sickness Drug and a Central Nervous System Depressant. 215
Crown, P., see Volavka, J., *et al.* 11

Davies, J. A., Navaratnam, V., Redfern, P. H.: A 24-Hour Rhythm in Passive-Avoidance Behaviour in Rats 211
Davis, T. R. A., Kensler, C. J., Dews, P. B.: Comparison of Behavioral Effects of Nicotine, d-Amphetamine, Caffeine and Dimethylheptyl Tetrahydrocannabinol in Squirrel Monkeys 51
Dews, P. B., see Davis, T. R. A., *et al.* 51
Dornbush, R., see Volavka, J., *et al.* 11
Downing, R. W., Rickels, K., Dreesmann, H.: Orthogonal Factors vs. Interdependent Variables as Predictors of Drug Treatment Response in Anxious Outpatients. 93
Dreesmann, H., see Downing, R. W., *et al.* 93
Drew, W. G., Miller, L. L., Baugh, E. L.: Effects of Δ^9-THC, LSD-25 and Scopolamine on Continuous, Spontaneous Alternation in the Y-Maze. . . 171

Ellison, G. D., see Sorenson, C. A. 313

Feldstein, S., see Volavka, J., *et al.* 11
File, S. E.: Interaction between Prior Experience and the Effects of Chlorpromazine on Exploration in the Rat 193
Fink, M., see Volavka, J., *et al.* 11
Friedhoff, A. J., see Branchey, L. 151

Genovese, E., Zonta, N., Mantegazza, P.: Decreased Antinociceptive Activity of Morphine in Rats Pretreated Intraventricularly with 5,6-Dihydroxytryptamine, a Long-Lasting Selective Depletor of Brain Serotonin. . . . 359
Gershon, S., see Sakalis, G., *et al.* 279
Glick, S. D., Zimmerberg, B., Charap, A. D.: Effects of α-Methyl-p-tyrosine on Morphine Dependence 365

Glow, P. H., Russell, A.: Drug Enhanced Sensory Contingent Bar Pressing: Comparing the Effect of Contingent and Noncontingent Sensory Change . 285
Goldberg, M. E., see Robichaud, R. C., *et al.* 157
Goldstein, D. B.: Convulsions Elicited by Handling: A Sensitive Method of Measuring CNS Excitation in Mice Treated with Reserpine or Convulsant Drugs 27
Gray, J. A., see Ridgers, A. 265

Hackmann, E., Wirz-Justice, A., Lichtsteiner, M.: The Uptake of Dopamine and Serotonin in Rat Brain during Progesterone Decline 183
Hajioff, J., see Lipsedge, M. S., *et al.* 67
Hefner, M. A., see Robichaud, R. C., *et al.* 157
Hindmarch, I., see Croucher, T. 215
Houser, F. L., see Houser, V. P. 133
Houser, V. P., Houser, F. L.: The Effects of Agents that Modify Muscarinic Tone upon Behavior Controlled by an Avoidance Schedule that Employs Signaled Unavoidable Shock 133
Houser, V. P., Paré, W. P.: Analgesic Potency of Sodium Salicylate, Indomethacin, and Chlordiazepoxide as Measured by the Spatial Preference Technique in the Rat 121
Huggins, P., see Lipsedge, M. S., *et al.* 67

Kelly, D., see Tyrer, P., *et al.* 237
Kensler, C. J., see Davis, T. R. A., *et al.* 51
Klein, M., see Milhaud, C., *et al.* 293
Kršiak, M., Borgesová, M.: Effect of Alcohol on Behaviour of Pairs of Rats . 201

Lader, M. H., see Bond, A. J. 223
Lal, H., see Puri, S. K. 113
Leonard, B. E.: Some Effects of the Hallucinogenic Drug 2,5-Dimethoxy-4-Methyl Amphetamine on the Metabolism of Biogenic Amines in the Rat Brain 33
Lichtsteiner, M., see Hackmann, E., *et al.* 183
Lipsedge, M. S., Hajioff, J., Huggins, P., Napier, L., Pearce, J., Pike, D. J., Rich, M.: The Management of Severe Agoraphobia: A Comparison of Iproniazid and Systematic Desensitization 67
Lorens, S. A., Mitchell, C. L.: Influence of Morphine on Lateral Hypothalamic Self-Stimulation in the Rat 271

Mantegazza, P., see Genovese, E., *et al.* 359
McKim, W. A.: The Effects of Scopolamine on Fixed-Interval Behaviour in the Rat: A Rate-Dependency Effect 255
Milhaud, C., Klein, M., Chapouthier, G.: Le comportement social de jeu des chimpanzés en tant que test psychopharmacologique. 293
Miller, L. L., see Drew, W. G., *et al.* 171
Mitchell, C. L., see Lorens, S. A. 271
Monti, J. M., Altier, H.: Flunitrazepam (Ro 5-4200) and Sleep Cycle in Normal Subjects 343

Napier, L., see Lipsedge, M. S., *et al.* 67
Navaratnam, V., see Davies, J. A., *et al.* 211
Naylor, R. J., see Costall, B. 161

Oglesby, M. W., Rosenberg, J., Winter, J. C.: Behavioral and Biochemical Effects of Chronic Administration of Bromide in the Rat 85
Oswald, I., see Allen, S. R. 1

Palermo Neto, J., Carvalho, F. V.: The Effects of Chronic Cannabis Treatment on the Aggressive Behavior and Brain 5-Hydroxytryptamine Levels of Rats with Different Temperaments 383
Paré, W. P., see Houser, V. P. 121
Park, S., see Sakalis, G., *et al.* 279
Pearce, J., see Lipsedge, M. S., *et al.* 67

Pike, D. J., see Lipsedge, M. S., *et al.* 67
Puri, S. K., Lal, H.: Effect of Dopaminergic Stimulation or Blockade on Morphine-Withdrawal Aggression 113

Rafaelsen, L., see Bech, P., *et al.* 373
Rafaelsen, O. J., see Bech, P., *et al.* 373
Redfern, P. H., see Davies, J. A., *et al.* 211
Rich, M., see Lipsedge, M. S., *et al.* 67
Rickels, K., see Downing, R. W., *et al.* 93
Ridgers, A., Gray, J. A.: Influence of Amylobarbitone on Operant Depression and Elation Effects in the Rat 265
Robichaud, R. C., Sledge, K. L., Hefner, M. A., Goldberg, M. E.: Propranolol and Chlordiazepoxide on Experimentally Induced Conflict and Shuttle Box Performance in Rodents 157
Rosenberg, J., see Oglesby, M. W., *et al.* 85
Russell, A., see Glow, P. H. 285

Sakalis, G., Chan, T. L., Gershon, S., Park, S.: The Possible Role of Metabolites in Therapeutic Response to Chlorpromazine Treatment 279
Schechter, M. D.: Transfer of State-Dependent Control of Discriminative Behaviour between Subcutaneously and Intraventricularly Administered Nicotine and Saline 327
Schubert, J.: Effect of Chronic Lithium Treatment on Monoamine Metabolism in Rat Brain 301
Singer, G., Coyle, I. R.: The Effect of Imipramine Administered before and during Pregnancy on Litter Size in the Rat. 337
Sledge, K. L., see Robichaud, R. C., *et al.* 157
Sorenson, C. A., Ellison, G. D.: Nonlinear Changes in Activity and Emotional Reactivity Scores following Central Noradrenergic Lesions in Rats . . . 313
Syme, G. J., see Syme, L. A. 81
Syme, L. A., Syme, G. J.: Effects of Chlorpromazine and Methamphetamine on Sociability in Rats 81

Taylor, M.: The Effects of Fenfluramine on Fixed Ratio Responding 351
Tyrer, P., Candy, J., Kelly, D.: A Study of the Clinical Effects of Phenelzine and Placebo in the Treatment of Phobic Anxiety 237

Volavka, J., Crown, P., Dornbush, R., Feldstein, S., Fink, M.: EEG, Heart Rate and Mood Change ("High") after Cannabis 11

Winter, J. C., see Oglesby, M. W., *et al.* 85
Wirz-Justice, A., see Hackmann, E., *et al.* 183

Zimmerberg, B., see Glick, S. D., *et al.* 365
Zonta, N., see Genovese, E., *et al.* 359

Indexed in Current Contents

Subject Index

A

Addiction 365
—, narcotic 113
Aggression 113
Aggresive behavior 383
Agoraphobia 67
Alcohol 201, 373
—, withdrawal 27
Alpha activity 11
Alternation, continuous spontaneous 171
Amines, biogenic 33
α-Amphetamine 51
D-Amphetamine 113
Amylobarbitone 265
—, sodium 285
Analgesia 121, 359
Animal model 313
—, temperament 383

B

Behavior 51
—, avoidance 133
—, individual 201
—, social 201
Behavioral tolerance 351
Benzodiazepines 343
Biting 113
Brain, monoamines 301
Bromide 85
Bulbocapnine 161
Butobarbitone 223

C

Caffeine 51
Cannabinol 51
Cannabis 373, 383
Cardriving, simulated 373
Catalepsy 161
Catecholamine, hypothesis of depression 313
—, metabolism 301
Caudate nucleus 151
Chimpanzee 293
Chlordiazepoxide 121, 157
Chlorpromazine 81, 85, 193, 279
—, sulphoxide 279
Clinical response 279
—, trials 237
Conditioning, fear 133
Conflict, experimental 157
Convulsions 27

D

Dependence 365
Depression 237
—, effect 265
Desensitization, systematic 67
Development 151
Dexamphetamine 285
Diazepam 93, 293
L-Dihydroxyphenylalanine 113
DL-Dihydroxyphenylalanine 113
5,6-Dihydroxytryptamine 359
Dimenhydrinate 215
2,5-Dimethoxy-4-Methylamphetamine 33
Disorders, affective 183
Dopaminergic neuropathway 113
Dopamine 183
Dramamine 215
Drug mixture 285
—, interactions 157

E

ED_{50} 121
EEG 1, 223
—, quantitative 11
Elation effect 265
Estimation of time 373
Estimation of, distance 373
Ethanol 151
Exploration 193
Extrapyramidal 161

F

Factor analysis 93
Fenfluramine 351
Fixed interval 255
—, ratio responding 351
Flunitrazepam 343
Flurazepam 223

H

Hallucinogens 33
Haloperidol 113
Hashish 11
Heart rate 11
Human subjects 1, 11, 67, 215, 223, 237, 279, 343, 373
7-Hydroxychlorpromazine 279
6-Hydroxydopamine 313
Hydroxylase, tyrosine 151
5-Hydroxytryptamine 301, 359
Hypnotic 1
Hypothalamus, lateral 271

I
Imipramine 337
Indomethacin 121
Insomnia 343
Intraventricular administration 327

L
Lithium 301
Litter size 337
LSD-25 171

M
Marijuana 11
Mesolimbic 161
Methadone 113
Methamphetamine 81
Methohexitone 67
Metoclopramide 161
α-Methyl-p-tyrosine 113, 365
Mice 27
Monkeys, squirrel 51, 133
Monoamine oxidase inhibitors 67, 237
Monoamines 85, 301
Mood 11
—, rating scale 223
Morphine 113, 271, 365
Motion sickness questionnaire 215
Motor function, impairment of 201

N
Neuroleptic agents 161
Nicotine 51, 327
Non-specific factors 93

P
Pentylenetetrazol 27
Perlapine 1
Perseveration, stimulus 171
Phenelzine 237
Phenobarbital 93
Phobic anxiety 237
Photographs 81
Picrotoxin 27
Pilocarpine 133
Placebo response 237
Prediction 93
Pregnancy 151, 337
Progesterone decline 183
Propranolol 157

R
Rabbits 359
Rate-dependency 255
Rats 33, 81, 85, 113, 121, 151, 157, 161, 171, 183, 193, 201, 211, 255, 265, 271, 285, 301, 313, 327, 337, 351, 359, 365, 383
Reaction, undrugged animals towards drugged ones and vice versa 201
Rearing 113
Regression, multiple 93
Reserpine 27
Residual effects 223
Responding, drug enhanced 285
Response feedback 285
—, passive avoidance 211
Reward magnitude 265
Rhythms, 24-hour 211

S
Salicylate, sodium 121
Scopolamine 133, 171, 255
—, methyl 133
Self-stimulation 271
Sensory contingent bar pressing 285
Serotonin 183, 359, 383
Shuttle-box 157
Sleep 1, 343
Sociability 81
Social behavior 293
Spatial preference technique 121
Spiral after effect 215
State-dependent behavior 327
Stress 383
Strychnine 27
Supersensitivity 113

T
Temazepam 215
Teratogenicity 337
Tetrahydrocannabinol 11, 51, 171
Tolerance, drug 271
Tryptophan 301

U
Uptake 183

V
Vocalization 113

Instructions to Authors

1. Papers will be published in **English, French or German.**

2. Authors should submit **manuscripts together with two copies.** The original illustration material (original drawings etc.) and two copies should be submitted together with the manuscript.

3. The text should be as **clear and concise** as possible. Both form and content of the paper should be carefully checked to exclude the need for corrections in proof. A charge will be made for changes introduced after the manuscript has been set in type.

4. **Manuscripts** should be typewritten, double-spaced, on one side of letter size paper and with wider margin on the left. The author should mark in the margin where figures and tables may be inserted. All pages should be numbered consecutively. Tables, footnotes and legends for illustrations should be typed (double-spaced) on separate pages. Use the metric system for text and figures.

5. The **first page** should bear:
the title; the name(s) of the author(s); the name of the laboratory where the work was carried out; a running title of not more than 67 typewriter strokes; footnotes to the title (marked by asterisks).

6. Each paper should be preceded by a brief **abstract** in English concerned with the methods used and with the experimental results which should be presented in such a way that it is possible for the reader to assess their significance. It should be as short as possible and should **not exceed 200 words.**
French and German articles should also have an **English translation of the title.**

7. Immediately following the abstract, some relevant **key words** should be supplied for subject indexing.

8. Articles dealing with **original investigations** should first state the problem concisely and arrange the material under Methods, Results, Discussion, References.

9. **Footnotes** should be kept to a minimum and numbered consecutively throughout the paper. Footnotes referring to the heading of the article are to be marked by asterisks.

10. The **bibliography** should include only work cited in the text. References should be listed alphabetically at the end of the paper as follows: *journal papers*—names and initials of all authors, full title, journal abbreviated in accordance with World Medical Periodicals, volume number, first and least page numbers, year in parentheses; *books*—names of authors, full title, edition, place, publisher, year. *Examples:*

Latz, A., Bain, G. T., Kornetsky, C.: Attenuated effect of chlorpromazine on conditioned avoidance as a function of rapid acquisition. Psychopharmacologia (Berl.) **14**, 23—32 (1960).

Fisher, S., Cole, J. O., Rickels, K., Uhlenhuth, E. H.: Drug set interaction: The effect of expectation on drug response in outpatients. In: Neuropsychopharmacology. Bradley, P. B., Flugle, F., and Hoch, P., eds., vol. 3, pp. 149—156. Amsterdam: Elsevier 1964.

Several publications by the same author or group of authors should be listed in chronological order; those that appear in the same year should be distinguished by the suffixes a, b, c etc. Citations in the text should be given in parentheses, e.g. (Beckman, 1958; Brown, 1963), except when the author's name is part of a sentence, e.g. "Man (1966) reported that . . ." When a paper with more than two authors is cited, all authors are named the first time, but subsequently only the first author, e.g. (Miller *et al.*, 1963).

11. Figures should be separated from the text and numbered. They should be restricted to a minimum. Descriptions in captions should not be expanded in the text, nor should the same data be given in both graph and table form. Coloured or previously published illustrations are not usually accepted. Original drawings and graphs should be drawn in Indian ink with lines of uniform thickness. Where possible, **figures should be grouped,** bearing in mind maximum display area is 108 × 177 mm ($4^1/_4 \times 7''$). In general it should be assumed that the same degree of reduction will apply to all figures in the same paper. Inscriptions should allow for any reduction in scale—a capital letter should be about 1.8 mm high in the final version. If figures have to be redrawn for the blockmaker, this may cause considerable delay in publication. Photographs should be sharp, well-contrasted glossy prints at right angles. Authors should mark them with Letraset (Instant Lettering).

CURRENT CONTENTS® CLINICAL PRACTICE

A NEW SERVICE THAT MAKES CONTINUING MEDICAL EDUCATION EASIER

When it comes to patient care, you know you've got to stay on top of what's new. But with busy schedules giving less time for reading, it's easy to miss key journal articles relevant to your work. *Current Contents/Clinical Practice* is an easy way to keep up with what's being published.



Each week—in an easy-to-scan, pocket-sized format, *CC®/CP* will bring you reproduced *tables of contents* from 700 of the world's most important clinical journals. By spending less than an hour with *CC/CP*—it's ideal for browsing between rounds and work-ups—you'll efficiently organize your reading. No need to handle a single journal until you're ready to read the articles you've preselected by examining titles on contents pages. And you'll be able to see what's in journals you don't normally check. The hard-to-get ones. The foreign ones.

For less than $3 a week you can make *sure* you find out what's new in patient care while it's still new. Subscribe today.

©1972 ISI

Please enter my order for *Current Contents®/Clinical Practice* and invoice me later. 337

- U.S.A., Canada, & Mexico: $135 per year
- All other locations: $165 per year

☐ 2 years – save 5% ☐ 3 years – save 10% ☐ 4 years – save 15% ☐ 5 years – save 20% ☐ 6 years – save 25%

☐ Please send information on discounts available for group subscriptions.

Name_____

Organization_____

Address_____

City_____ State_____

Zip_____ Country_____

GUARANTEE: Your money refunded in full if you are not satisfied with *Current Contents/Clinical Practice* after receiving six of the weekly issues.

ISI® Institute for Scientific Information
325 Chestnut Street, Philadelphia, Pennsylvania 19106 U.S.A. Tel.: (215) 923 3300

The journal you are reading and 5000 others are regularly covered in *CURRENT CONTENTS®*.

Responsible for advertisements: L. Siegel, D-1000 Berlin 15, Kurfürstendamm 237
Telephone: (030) 883 01 31, Telex: 01-85 411
Springer-Verlag, Berlin, Heidelberg, New York
Printed in Germany by Wiesbadener Graphische Betriebe GmbH, D-6200 Wiesbaden

© by Springer-Verlag, Berlin Heidelberg 1973